Saturday, September 15th, 2012 Breakfast teaching courses
| |
| 07:30-09:00 |
|
Clinical management of Huntington’s disease Martha Nance (Minneapolis, USA) | | |
| 07:30-09:00 | |
Differential diagnosis of chorea Ruth Walker (New York, USA) | | |
| 07:30-09:00 | |
Behavioral assessment and management of behavioral issues Karen Anderson (Baltimore, USA) | | |
| 07:30-09:00 |
|
Training on HD assessments including HD-CC David Craufurd (Manchester, UK), Ralf Reilmann (Münster, Germany), Jennifer Thompson (Manchester, UK) and Oliver Quarrell (Sheffield, UK) |
Plenary Session V: 'Understanding and manipulating the pathogenic process in Huntington’s disease'
| Chair: David Rubinsztein (Cambridge, UK) |
| |
| 09:15-09:45 |
|
Huntingtin Elena Cattaneo (Milan, Italy) |
| |
| 09:45-10:15 |
|
Post-translational modifications of huntingtin
Frédéric Saudou (Paris-Orsay, France) |
| |
| 10:15-10:45 |
|
Stem cells for basic research on HD Lisa Ellerby (Novato, USA), Leslie Thompson (Irvine, USA) |
| |
| 10:45-11:15 |
|
Tea/Coffee Break |
| |
Plenary Session VI: 'Keynote presentation'
| Chair: Neil Aronin (Boston, USA) |
| |
| 11:15-12:00 |
|
Updates on lowering huntingtin (htt) levels Beverley Davidson (Iowa, USA) |
| |
| 12:00-12:30 |
|
Open discussion |
| |
Poster Viewing
| Chairs: Marcy MacDonald (Boston, USA), Marian DiFiglia (Boston, USA), Blair Leavitt (Vancouver, Canada) |
| |
| 12:30-14:00 |
|
Poster Viewing & Guided Poster Tours |
| |
| 12:30-14:00 |
|
Buffet Style Lunch |
| | Short communications II: Scientific presentations
| Chair: Jim Gusella (Boston, USA) |
| |
| 14:00-14:15 |
|
HDAC4 interacts with huntingtin and HDAC4 reduction decreases cytoplamsic aggregation and rescues synaptic dysfunction in HD mouse models Gillian Bates (London, UK) | | |
| 14:15-14:30 | |
Aging pathway and poly-Q neurotoxicity Ellen Nollen (Groningen, The Netherlands) | | |
| 14:30-14:45 | |
NeuroNet and its potential for the study of neurodegeneration Erich Wanker (Berlin, Germany) | | |
| 14:45-15:00 |
|
Phenotyping neural networks in an ovine model of HD Nicholas Perentos (Cambridge, UK) |
Plenary Session VII: 'Therapeutic development programs in Huntington’s disease'
| Chair: Cristina Sampaio (Princeton, USA) |
| |
| 15:00-16:30 |
|
Overview of CHDI drug development programs Robert Pacifici (Los Angeles, USA) |
| |
|
|
Data blitz |
|
|
Htt lowering: Medtronic-Alnylam/Isis/CHDI - Douglas Macdonald |
|
|
Sirt1-inhibition: SienaBiotech - Andrea Caricasole |
|
|
PDE-10-inhibition: Pfizer - Christopher J. Schmidt |
|
|
PDE-4-inhibition: GSK - Frank Gray |
|
|
Pridopidine: NeuroSearch - G. Bernhard Landwehrmeyer |
|
|
Bupropion: ACTION-HD - Josef Priller |
|
|
Further topics |
| |
|
|
Round table discussion Moderation: Robert Pacifici and Cristina Sampaio |
| |
| 16:30-17:00 |
|
Tea/Coffee Break |
| |
Plenary Session VIII: 'EHDN Business Meeting'
| Chair: Stephen Dunnett (Cardiff, UK) |
| |
| 17:00-17:30 |
|
EHDN Update EC elections, SBAC elections Structure of EHDN Bernhard Landwehrmeyer (Ulm, Germany) |
| 17:30-17:45 |
|
HD guidelines Daniela Rae (Aberdeen, UK) |
| 17:45-18:00 |
|
Presentation of the HDYO website Matt Ellison (Coventry, UK) |
| |
Roundup II
| 18:00-18:30 |
|
Lessons of the day Edward Wild (London, UK) and Jeff Carroll (Bellingham, USA) | | |
Poster viewing
| 18:30-22:30 |
|
Poster viewing with Bar and Food Buffet |
|